Resistin In Multiple Sclerosis|OMICS International|Journal Of Neurology And Neurophysiology

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Resistin In Multiple Sclerosis

Adipocytokines are cytokine-like mediators that link adipose tissue function with inflammatory and autoimmune processes, and have a suggested role in the pathogenesis of multiple sclerosis (MS). Adipocytokines are cytokine-like mediators produced by adipose tissue and are involved in inflammation, immune response, and metabolism. Leptin, adiponectin, and resistin belong to the most abundant family of adipocytokines that link adipose tissue function with inflammatory and autoimmune processes. Leptin is recognized as an immunendocrine mediator. Neurological autoimmune disorders are associated with increased concentrations of adipocytokines with a particular significance for resistin in RRMS patients. Routine methylprednisolone treatment induced a harmful effect that led to an increase in leptin levels. First line immunomodulatory treatment by reducing resistin concentration limits the immune response mediated by adipocytokines in RRMS patients. Resistin concentrations are reduced by first line immunomodulatory treatment of RRMS, which produces a beneficial milieu of inflammatory and metabolic processes.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on April, 2021